Pneumonia, Bacterial, Bronchitis, Chronic
Conditions
Keywords
pneumonia, Spneumoniae, bronchitis, telithromycin, azithromycin
Brief summary
To measure the speed of bacterial eradication from the respiratory tract after administration of azithromycin or telithromycin.
Detailed description
To Evaluate the relationship between rate of S. pneumoniae killing in sputum, PK/PD, and clinical response of oral telithromycin and azithromycin in patients with AECB or CAP and to determine if there is a difference in the rates of infection site bacterial killing (as described above) between these 3 antibiotics against penicillin- and erythromycin-resistant S.pneumoniae
Interventions
DRUGazithromycin
250 mg tablets; 2 tablets on day 1 (500 mg load) and 1 tablet QD on days 2-5
DRUGtelithromycin
400 mg tablets; 2 tablets once daily (QD) for 5 days
DRUGClarythromycin
500 mg extended release tablets; 2 tablets QD for 7 days
Sponsors
Sanofi
CPL Associates
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Adult patients, either males or non-pregnant females, aged 18 to 75 years of age with clinical findings of CAP or AECB who are amenable to serial nasopharyngeal and oropharyngeal sampling and having positive Binax-NOW tests indicating infection with Streptococcus pneumoniae * Patients with a medical history and clinical findings consistent with a respiratory tract infection. A patient with advanced COPD, repeated exacerbations by history, a BINAX-NOW test consistent with S. pneumoniae and/or proven culture positivity for S. pneumoniae may be enrolled * All patients (CAP or AECB) must produce purulent sputum and be positive on the Urinary BINAX-NOW assay. * The female patient of child bearing potential must agree to use an accepted method of contraception (i.e., oral or implanted contraceptive with a barrier method, spermicide and barrier methods, or IUD). The patient must agree to continue with the same method throughout the study.
Exclusion criteria
* Baseline sputum cultures known to be negative for S. pneumoniae, or negative urinary BINAX-NOW. * Patients with a microbiologically documented pathogen known prior to inclusion to be resistant to any of the study medications. * History of hypersensitivity to macrolides, azalides, ketolide antibiotics or history of serious hypersensitivity reaction to any drug. * Pre-existing impaired hepatic function or impaired renal function CCL \<20ml/min * Patients who will require on-study treatment with medications known to have contraindicated drug interactions with telithromycin * Treatment with more than one dose of an antimicrobial prior to entry into the study Others as per protocol
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Time to bacterial eradication | 11-18 days |
| Bacteriologic outcome | 11-18 days |
Countries
United States
Outcome results
None listed